Trial Profile
An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RECORD-3
- Sponsors Novartis
- 16 Oct 2018 Results published in the Clinical Cancer Research
- 10 Feb 2018 Results assessing mutation status integration into the MSKCC model using two large clinical trial datasets (COMPARZ and RECORD3; n=487) presented at the 2018 Genitourinary Cancers Symposium
- 29 Jan 2018 Results (n=471) assessing final overall survival analysis for secondary endpoints were, published in the Annals of Oncology.